Method of treating diabetes with tissue-selective insulin analogs
US5446020A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 23, 1993 |
| Grant date | Aug 29, 1995 |
| Priority date | — |
| Expiry date | Jun 23, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Human insulin analogs are disclosed. These analogs are tissue-selective. Accordingly, pharmaceutical formulations containing the analogs of the invention provide superior clinical benefits as compared to human insulin when used in the treatment of patients suffering from diabetes. The analogs are modified at amino residue A12, A15 or A19, are different from the naturally occurring residue at said position, and are hepatoselective. Also disclosed are human insulin analogs modified at amino acid residues A12 or A14 or amino acid residues A10 and A13 different from naturally occurring residues or residues at said position or positions and are peripheral selective. DNA sequences and microorganisms comprising sequences coding for human insulin analogs are also provided. Processes for preparing the human insulin analogs are described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.